ArticleFrontiers in aging neuroscience2026
Multi-omics identification of novel biomarkers and therapeutic targets for Parkinson's disease: from transcriptome to drug interaction.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Parkinson's disease (PD) is a progressive neurodegenerative disorder with limited therapeutic options. Acupuncture may serve as a complementary intervention, but its molecular mechanisms remain unclear. This study integrated bulk and single-cell transcriptomic datasets to identify PD-associated diagnostic candidate genes and explore their relationship with acupuncture-related temporal expression patterns. Methods: PD-associated differentially expressed genes were identified from GSE68719. Time-series analysis of GSE178470 characterized ascending or descending expression trajectories in longitudinal blood transcriptomes from one patient with PD sampled at baseline and after 5 and 8 acupuncture sessions. Genes showing directionally opposite patterns between PD-associated dysregulation and post-acupuncture temporal changes were intersected, followed by feature selection using LASSO, Random Forest, Boruta, and XGBoost. Diagnostic performance was evaluated in GSE68719. Single-cell transcriptomic analysis, molecular docking, and MPP+-treated SH-SY5Y cells were used for further exploratory characterization and validation. Results: Eleven candidate genes were identified, of which four were prioritized by machine-learning approaches. The four-gene panel discriminated patients with PD from healthy controls in GSE68719, with an apparent AUC of 0.873, sensitivity of 0.690, specificity of 0.864, accuracy of 0.795, precision of 0.769, F1 score of 0.727, and Brier score of 0.134. These metrics reflect PD-versus-control classification rather than prediction of acupuncture response. Single-cell analysis mapped cell type-specific expression across human midbrain populations. Molecular docking provided exploratory predicted binding poses. BAG3 and HSPB1 were upregulated in MPP+-treated SH-SY5Y cells. Discussion: These findings provide an integrative framework for prioritizing PD-associated candidate genes with exploratory acupuncture-related temporal patterns. Further validation in larger longitudinal cohorts and functional studies is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.